Symptoms and General Pathology

All Conditions

Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Hypoxia

Uterine Cervical Neoplasms

Carcinoma, Renal Cell

Uterine Neoplasms

Kidney Neoplasms

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Urologic Neoplasms

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Renal Cell Carcinoma

Micronutrients

Anti-Infective Agents

All Drugs and Chemicals

Iodine

Cadexomer iodine

Patients will receive 124IAZGP(124I-Iodo-Azomycin Galacto-Pyranoside).

You will receive the radioactive tracer through an injection in your vein. Blood (about 5 tablespoons in all) will be taken after the radioactive tracer has been given. Over the course of study day 1, bloods will be drawn 8 times and then 4 more times on study day 2. You will undergo three \*IAZGP PET scans, one shortly after you receive the injection, one later the same day and one the following day. Each scan will take about an hour. This means you would be asked to come back 2 days in a row.

124I-Iodo-Azomycin Galacto-Pyranoside

Heiko Schöder, MD

The purpose of this study is to evaluate low oxygen areas called hypoxia within the tumor. These low oxygen areas are thought to be the reason why tumors are more resistant to radiation treatment. A tracer is an extremely small quantity of a substance. Tracer to which radioactivity has been attached may be used to "trace" events in the body. A tracer called iodo-azomycin galactopyranoside (or \*IAZGP) appears to be able to detect low oxygen areas within tumor.

Radioactive iodine in this molecule can be detected by an imaging technique called a PET scan. This present study involves obtaining three scans using this new imaging technique. The goal of carrying out many scans is to determine which scan will best show any areas in your tumor that may have low levels of oxygen.

Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors

National Cancer Institute (NCI)

Memorial Sloan Kettering Cancer Center

Gestational Trophoblastic Disease

Trophoblastic Neoplasms

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Pregnancy Complications, Neoplastic

30 patients survived GTD post treatment for 0 - 5 years.

30 patients survived GTD post treatment 6 - 10+ years.

A patient questionnaire, which includes validated instruments. Data collection methods are as follows:

* In person at the medical appointment
* Over the telephone
* Mailed with self-addressed return envelope and prepaid postage
* E-mailed and returned by e-mail, fax or self-addressed envelope and pre-paid postage

questionnaire

Elizabeth Jewell, MD

The purpose of this study is to collect information on the effects of treatment for gestational trophoblastic disease (GTD). We plan to use the findings from this study to better understand GTD survivors' health and quality of life.

We would like to know more about the health, quality of life and pregnancies of women treated for GTD. This information will be used to try and improve the treatments for women who have this disease.

A Global Assessment of Medical, Emotional and Reproductive Concerns in Gestational Trophoblastic Disease Survivors

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors	NCT00588276	Cervical Cancer HEENT Cancer Renal Cancer Uterine Cancer CERVIX UTERI NO... RECTUM	124I-Iodo-Azomy...	18 Years -	Memorial Sloan Kettering Cancer Center
A Global Assessment of Medical, Emotional and Reproductive Concerns in Gestational Trophoblastic Disease Survivors	NCT00706875	Uterine Cancer Cervix Uteri No... Gestational Tro...	questionnaire questionnaire	18 Years - 60 Years	Memorial Sloan Kettering Cancer Center
A Global Assessment of Medical, Emotional and Reproductive Concerns in Gestational Trophoblastic Disease Survivors	NCT00706875	Uterine Cancer Cervix Uteri No... Gestational Tro...	questionnaire questionnaire	18 Years - 60 Years	Memorial Sloan Kettering Cancer Center

Spots Global Cancer Trial Database for cervix uteri nos